Business Wire

c-LEcta Expands Product Range to Include Additional Enzyme NuCLEANase®

Share

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, is launching a newly developed enzyme product. NuCLEANase® is a highly active endonuclease that degrades all forms of DNA and RNA. This results in a wide range of applications in the food, feed and consumer care industries, with correspondingly high market potential. c-LEcta is thus once again demonstrating its ability to bring high-quality enzyme products to the market.

NuCLEANase® is a specially optimized enzyme preparation that cleaves all types of DNA. It can be used to remove DNA residues from products manufactured with the help of microorganisms: These include enzymes for the food and feed industries, but also vitamins and amino acids, for example. Based on its proprietary technology platform ENESYZ, c-LEcta offers this nuclease in industrial quantities, high quality and at affordable prices for all customers for the first time. NuCLEANase® supports any process requiring the removal of DNA and RNA, making it a reliable tool for various groups of customers.

Our strategy of focusing on the development of our own products has proven successful in recent years,” emphasizes Dr. Marc Struhalla, founder and CEO of the company. “Following the successes of the Plug & Play Biocats® and the DENARASE® product family, we are now adding another attractive product to our range with NuCLEANase®, for which we ourselves are responsible for marketing and sales. NuCLEANase is another example of the performance of our technology platform ENESYZ.”

Dr. Biljana Mitrova, Business Development, adds: “We see great potential for our new enzyme product NuCLEANase® . NuCLEANase® is the perfect tool to support any process in industry where the efficient removal of. nucleic acids’ residues, is required, or if an increase in the amount of nucleotides is desired. In yeast products, for example: Yeasts contain many valuable nutrients, but also nucleic acids, which can indirectly promote gout and kidney stones. NuCLEANase® breaks them down so they can be removed easily.” There are other applications, as well: In yeast flavorings, the degraded nucleic acids improve the flavor profile in small quantities; in larger quantities, they are used in animal feed as health-promoting additives.

NuCLEANase® also enables the removal of stubborn biofilms, i.e., films that settle on surfaces like plaque. After treatment with NuCLEANase ® , the tough coatings come off more easily and can be removed efficiently. Biofilms are problematic, for example, in the food industry or in the medical environment, but they also occur on human teeth and skin, so it is expected that NuCLEANase® can also be used to advantage in personal care and cosmetic products.

All information about the product is available at www.nucleanase.com.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

cometis AG
Daniela Simonsen
Phone: +49 (0) 611 - 205855 – 35
Fax: +49 (0) 611 - 205855 – 66
Email: simonsen@cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release

Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release

Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release

Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye